FrancophonIA/ELRC3.0 huggingface dataset:
English: For further information, see the summary of product characteristics (also part of the EPAR).
Croatian: Dodatne informacije pročitajte u sažetku opisa svojstava lijeka (također dio EPARa).
English: For practical information about using Holoclar, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o korištenju lijeka Holoclar pročitajte u uputi o lijeku, odnosno obratite se svom liječniku ili ljekarniku.
English: 06 August 2014
Croatian: 06. kolovoza 2014.
English: The European Commission issued a decision on 06 August 2014.
Croatian: Europska komisija je usvojila odluku dana 06. kolovoza 2014.
English: Why was Dexamed reviewed?
Croatian: Zašto je Dexamed pregledan?
English: What is Dexamed?
Croatian: Što je Dexamed?
English: On 22 May 2014, the European Medicines Agency completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Dexamed (dexamfetamine sulphate).
Croatian: Dana 22. svibnja 2014., Europska agencija za lijekove zaključila je arbitražni postupak nakon neslaganja država članica Europske unije (EU) u vezi s odobrenjem lijeka Dexamed (deksamfetamin sulfat).
English: This is a procedure where one European country (the ‘reference Member State', in this instance the United Kingdom) assesses a medicine with a view to granting a marketing authorisation that will be valid in this country as well as in other European countries (the ‘concerned Member States', in this instance Denmark, Finland, Ireland, Luxembourg, the Netherlands, Norway, Spain, and Sweden).
Croatian: Ovo je postupak u kojem jedna država članica Europske unije („referentna država članica”, u ovom slučaju Ujedinjena Kraljevina) ocjenjuje lijek sa ciljem izdavanja odobrenja za stavljanje lijeka u promet koje će biti valjano u dotičnoj državi kao i u drugim europskim državama („članicama sudionicama u postupku”, u ovom slučaju Danskoj, Finskoj, Irskoj, Luksemburgu, Nizozemskoj, Norveškoj, Španjolskoj i Švedskoj).
English: However, the Member States were not able to reach an agreement and the UK medicines regulatory agency referred the matter to the CHMP for arbitration on 10 June 2013.
Croatian: No, države članice nisu uspjele postići sporazum te je regulatorna agencija za lijekove Ujedinjene Kraljevine uputila predmet CHMP-u na arbitražu dana 10. lipnja 2013.
English: Dexamed is a medicine that contains the active substance dexamfetamine sulphate.
Croatian: Dexamed je lijek koji sadrži djelatnu tvar deksamfetamin sulfat.
English: ADHD is a condition that mainly affects children, resulting in a persistent inability to concentrate, hyperactivity and impulsive behaviour.
Croatian: ADHD je stanje koje je uglavnom zahvaća djecu, a rezultira u trajnoj nesposobnosti koncentracije, hiperaktivnosti i impulzivnog ponašanja.
English: Educational material will also be given to pharmacists, parents and carers to help them identify any potential abuse or improper use of Dexamed.
Croatian: Edukacijski materijali bit će dostavljeni također i ljekarnicima, roditeljima i skrbnicima kako bi im se pomoglo pri identificiranju potencijalne zlouporabe ili neprimjerene uporabe lijeka Dexamed.
English: Kohne Pharma GmbH submitted Dexamed to the UK medicines regulatory agency for a decentralised procedure.
Croatian: Tvrtka Kohne Pharma GmbH dostavila je lijek Dexamed regulatornoj agenciji za lijekove Ujedinjene Kraljevine radi provođenja decentraliziranog postupka.
English: It is to be available as tablets (5 mg) for the treatment of children between 6 and 17 years of age who have attention deficit hyperactivity disorder (ADHD) and in whom methylphenidate (another medicine for ADHD) was not effective (second-line treatment).
Croatian: Treba biti dostupan kao tablete (5 mg) za liječenje djece u dobi između 6 i 17 godina koji pate od poremećaja hiperaktivnosti i deficita pozornosti (ADHD) te kod kojih metilfenidat (drugi lijek za ADHD) nije bio djelotvoran (druga linija liječenja).
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Dexamed outweigh its risks, and the marketing authorisation can be granted in the United Kingdom and in the following countries: Denmark, Finland, Ireland, Luxembourg, the Netherlands, Norway, Spain and Sweden.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji zaključilo je da koristi lijeka Dexamed nadmašuju s njim povezane rizike, te odobrenje za stavljanje lijeka u promet može biti izdano u Ujedinjenoj Kraljevini i niže navedenim državama: Danskoj, Finskoj, Irskoj, Luksemburgu, Nizozemskoj, Norveškoj, Španjolskoj i Švedskoj.
English: Dexamfetamine belongs to a group of medicines called ‘psychostimulants' and is thought to work by activating certain areas of the brain that control attention and concentration, thus helping to reduce impulsive behaviour.
Croatian: Deksamfetamin se ubraja u grupu lijekova naziva „psihostimulansi” te se smatra da djeluju aktiviranjem određenih područja mozga koja kontroliraju pažnju i koncentraciju, te na ovaj način pomažu u smanjivanju impulzivnog ponašanja.
English: These measures include starting and regularly monitoring treatment with Dexamed under the supervision of a doctor experienced in treating childhood and adolescent behaviour disorders.
Croatian: Ove mjere uključuju početak i redovito praćenje liječenja lijekom Dexamed uz nadzor liječnika iskusnog u liječenju poremećaja ponašanja u djece i adolescenata.
English: The CHMP also noted that evidence from studies and clinical practice is available to show that dexamfetamine is effective in ADHD, including in patients in whom other treatments have failed.
Croatian: CHMP je također napomenuo da je dokaz iz ispitivanja i kliničke prakse dostupan kako bi se dokazalo da je deksamfetamin djelotvoran u liječenju ADHD-a, uključujući i u bolesnika kod kojih druge terapije nisu bile uspješne.
English: Furthermore, the company that markets Dexamed will conduct additional studies on the risk of abuse for this medicine.
Croatian: Nadalje, tvrtka koja stavlja lijek Dexamed u promet provest će dodatna ispitivanja o riziku od zlouporabe ovog lijeka.
English: Although the CHMP acknowledged that there is a risk of abuse and dependence with Dexamed, it concluded that the risk minimisation measures proposed to mitigate this risk are adequate.
Croatian: Iako je CHMP potvrdio da je rizik zlouporabe i ovisnosti prisutan s lijekom Dexamed, zaključio je da su predložene mjere za smanjivanje rizika primjerene kako bi se ovaj rizik minimizirao.
English: Therefore, based on evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the benefits of Dexamed outweigh its risks for second-line treatment of ADHD and recommended that the marketing authorisation be granted in all concerned Member States.
Croatian: Slijedom navedenog, na temelju ocjene trenutno dostupnih podataka i znanstvene rasprave unutar Odbora, CHMP je zaključio da koristi lijeka Dexamed nadmašuju s njim povezane rizike za drugu liniju liječenja ADHD-a te je preporučilo izdavanje odobrenja za stavljanje lijeka u promet u svim državama članicama.
English: The grounds for the referral were concerns raised by the Netherlands that Dexamed presents a higher risk for abuse and dependence compared with other ADHD treatments, and that the data submitted to support the application did not provide sufficient evidence to demonstrate its effectiveness as a second-line treatment for ADHD.
Croatian: Razlog za postupak upućivanja je zabrinutost iznijeta od strane Nizozemske da Dexamed predstavlja veliki rizik od zlouporabe i ovisnosti u usporedbi s drugim liječenjima ADHD-a, te da podaci dostavljeni u prilog prijave nisu pružili dovoljno dokaza kako bi se demonstrirala učinkovitost druge linije liječenja za ADHD.
English: The experts' group advised that while there is some evidence that medicines of the same type as Dexamed are more likely to induce dependence than other treatments for ADHD, based on clinical practice the risk of developing dependence in patients treated with dexamfetamine is considered to be low and could be adequately managed with appropriate risk minimisation measures.
Croatian: Prema mišljenju grupe stručnjaka, iako postoje neki dokazi da lijekovi iste vrste kao Dexamed češće izazivaju ovisnost u odnosu na druga liječenje ADHD-a, na temelju kliničke prakse rizik razvoja ovisnosti u bolesnika liječenih deksamfetaminom smatra se niskim te se njime može upravljati na odgovarajući način pomoću primjerenih mjera za smanjivanje rizika.
English: Educational material will be provided to doctors to help them decide if treatment with Dexamed is appropriate and to monitor patients receiving the medicine.
Croatian: Edukacijski materijali dostavit će se liječnicima kako bi im se olakšalo donošenje odluke je li terapija lijekom Dexamed primjerena te praćenje bolesnika koji primaju lijek.
English: These conclusions were supported by a group of experts in childhood and adolescent behavioural problems consulted by the CHMP.
Croatian: Grupa stručnjaka na području problema u ponašanju djece i adolescenata, čiji je savjet zatražio CHMP, podržala je ove zaključke.
English: - In general, taking too much Axura should not result in any harm to you.
Croatian: - Općenito, uzimanje previše Axure ne bi Vam trebalo naškoditi.
English: Axura with food and drink
Croatian: Axura s hranom i, pićem
English: If you take more Axura than you should
Croatian: Ako uzmete više Axure nego što ste trebali
English: Axura is not recommended for children and adolescents under the age of 18 years.
Croatian: Axura se ne preporučuje za djecu i adolescente mlađe od 18 godina.
English: Always take Axura exactly as your doctor has told you.
Croatian: Uvijek uzimajte Axuru točno onako kako Vam je rekao Vaš liječnik.
English: The safety and efficacy of Axura in children aged below 18 years has not been established.
Croatian: Sigurnost i djelotvornost Axure u djece mlađe od 18 godina nije ustanovljena.
English: Other medicines and Axura
Croatian: Drugi lijekovi i Axura
English: - If you find you have forgotten to take your dose of Axura, wait and take your next dose at the usual time.
Croatian: Ako ustanovite da ste zaboravili uzeti dozu Axure, pričekajte i uzmite sljedeću dozu u uobičajeno vrijeme.
English: In another case of a large overdose, the patient also survived and recovered.
Croatian: U drugom slučaju predoziranja velikom dozom bolesnik je također preživio te se oporavio.
English: Continue to take Axura as long as it is of benefit to you.
Croatian: Nastavite uzimati Axuru onoliko dugo koliko od nje imate koristi.
English: In case of signs and symptoms of general central nervous system (CNS) overstimulation, careful symptomatic clinical treatment should be considered.
Croatian: U slučaju znakova i simptoma opće pretjerane stimulacije središnjeg živčanog sustava (SŽS), treba razmotriti pažljivo simptomatsko kliničko liječenje.
English: <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Croatian: (≥1/10 000 i <1/1 000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
English: Content of the pack and other information What Axura contains
Croatian: Sadržaj pakiranja i druge informacije Što Axura sadrži
English: In particular, Axura may change the effects of the following medicines and their dose may need to be adjusted by your doctor:
Croatian: Posebice, Axura može promijeniti učinak sljedećih lijekova, te će liječnik možda morati prilagoditi njihovu dozu:
English: What Axura looks like and contents of the pack
Croatian: Kako Axura izgleda i sadržaj pakiranja
English: The Axura treatment initiation pack is only to be used for the beginning of the treatment with Axura.
Croatian: Pakovanje ovaj lijek za početak liječenja se treba koristiti samo na početku liječenja Axurom.
English: If you go into hospital, let your doctor know that you are taking Axura.
Croatian: Ako dođete u bolnicu, obavijestite svog liječnika da uzimate Axuru.
English: Axura belongs to a group of medicines known as anti-dementia medicines.
Croatian: Axura se ubraja u skupinu lijekova poznatih kao lijekovi protiv demencije.
English: If you forget to take Axura
Croatian: Ako ste zaboravili uzeti Axuru
English: Axura contains sorbitol
Croatian: Axura sadrži sorbitol
English: Also, Axura may change your reactivity, making driving or operating machinery inappropriate.
Croatian: Axura također može promijeniti Vašu sposobnost reagiranja, što čini upravljanje vozilima i rad sa strojevima neprikladnima.
English: Date of first authorisation: 17 May 2002 Date of latest renewal: 17 May 2007
Croatian: Datum posljednje obnove: 17. svibanj 2007.
English: Axura oral solution is available in bottles of 50 ml, 100 ml or a multipack of 500 ml (10 x 50 ml).
Croatian: Axura oralna otopina dostupna je u bocama od 50 ml, 100 ml ili višestruko pakiranje od 500 ml (10 x 50 ml).
English: EU/1/02/218/011 500 ml (10 bottles of 50 ml)
Croatian: EU/1/02/218/011 500 ml (10 boca od 50 ml)
English: The most frequently occurring adverse reactions with a higher incidence in the Axura group than in the placebo group were dizziness (6.3% vs 5.6%, respectively), headache (5.2% vs 3.9%), constipation (4.6% vs 2.6%), somnolence (3.4% vs 2.2%) and hypertension (4.1% vs 2.8%).
Croatian: Nuspojave koje su se najčešće pojavljivale s većom incidencijom u skupini bolesnika liječenih Axurom nego u skupini koja je uzimala placebo bile su omaglica (6,3% naspram 5,6%), glavobolja (5,2% naspram 3,9%), konstipacija (4,6% naspram 2,6%), somnolencija (3,4% naspram 2,2%) i hipertenzija (4,1% naspram 2,8%).
English: Excipients: Each one millilitre of solution contains 100 mg sorbitol (E 420) and 0.5 mg potassium, see section 4.4.
Croatian: Pomoćne tvari: svaki mililitar otopine sadrži 100 mg sorbitola (E 420) i 0,5 mg kalija, vidjeti dio 4.4.
English: These events have been reported in patients treated with Axura.
Croatian: Ovi su događaji prijavljivani kod bolesnika liječenih Axurom.
English: - If you take a large overdose of Axura, contact your doctor or get medical advice, as you may need medical attention.
Croatian: Ako ste uzeli preveliku dozu Axure, javite se Vašem liječniku za savjet, jer bi Vam mogla zatrebati medicinska pomoć.
English: Talk to your doctor or pharmacist before taking Axura - if you have a history of epileptic seizures - if you have recently experienced a myocardial infarction (heart attack), or if you are suffering from congestive heart failure or from an uncontrolled hypertension (high blood pressure).
Croatian: Obratite se svom liječniku ili ljekarniku prije nego uzmete Axuru ako u anamnezi imate epileptičke napadaje, - ako ste nedavno imali infarkt miokarda (srčani udar), ili ako bolujete od kongestivnog zatajenja srca ili nekontrolirane hipertenzije (povišeni krvni tlak).
English: At the beginning of treatment you will start by using Axura 5 mg film-coated tablets once a day.
Croatian: Liječenje ćete započeti korištenjem Axura filmom obloženih tableta od 5 mg jedanput na dan.
English: In patients with mild or moderate hepatic impaired function (Child-Pugh A and Child-Pugh B) no dose adjustment is needed.
Croatian: Oštećenje jetrene funkcije Kod bolesnika s blagim ili umjerenim oštećenjem jetrene funkcije (Child-Pugh A i Child-Pugh B) nije potrebna prilagodba doze.
English: Furthermore, Axura has minor to moderate influence on the ability to drive and use machines such that outpatients should be warned to take special care.
Croatian: Nadalje, Axura ima blagi do umjereni utjecaj na sposobnost upravljanja vozilima i rada sa strojevima pa ambulantne bolesnike treba upozoriti da na to obrate posebnu pozornost.
English: If you suffer from renal impairment (kidney problems), your doctor should closely monitor your kidney function and if necessary adapt the memantine doses accordingly.
Croatian: Ako imate oštećenje bubrežne funkcije (probleme s bubrezima), liječnik treba pažljivo funkciju Vaših bubrega i ovisno o njoj, prilagoditi dozu memantina, ako je to potrebno.
English: What you need to know before you take Axura Do not take Axura
Croatian: Što morate znati prije nego počnete uzimati Axuru Nemojte uzimati Axura
English: Adverse reactions are ranked according to system organ class, using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to
Croatian: Nuspojave su razvrstane prema klasifikaciji organskih sustava, konvencijuprema sljedećim skupinama učestalosti: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko
English: What is Axura used for
Croatian: Za što se Axura koristi
English: What Axura is and what it is used for What you need to know before you take Axura How to take Axura
Croatian: Što je Axura i za što se koristi Što morate znati prije nego počnete uzimati Axuru Kako uzimati Axuru
English: The recommended treatment dose of 20 mg per day is achieved by a gradual increase of the Axura dose during the first 3 weeks of treatment.
Croatian: Preporučena doza za liječenje od 20 mg dnevno postiže se postupnim povećanjem doze Axure tijekom prva 3 tjedna liječenja.
English: Axura should be administered once a day and should be taken at the same time every day.
Croatian: Axura se mora primjenjivati jednom dnevno i potrebno ju je uzimati svaki dan u isto vrijeme.
English: Axura acts on these NMDA-receptors improving the transmission of nerve signals and the memory.
Croatian: Axura djeluje na navedene NMDA receptore poboljšavajući prijenos živčanih signala i pamćenje.
English: What Axura is and what it is used for How does Axura work
Croatian: Što je Axura i za što se koristi Kako djeluje Axura
English: Daily doses of 20 mg lead to steady-state plasma concentrations of memantine ranging from 70 to 150 ng/ml (0.5-1 µmol) with large interindividual variations.
Croatian: Dnevne doze od 20 mg dovode do plazmatskih koncentracija memantina u stanju dinamičke ravnoteže u rasponu od 70 do 150 ng/ml (0,5-1 µmol) s velikim interindividualnim razlikama.
English: Axura should be taken once daily at the same time each day.
Croatian: Axura se mora uzimati jednom dnevno, svaki dan u isto vrijeme.
English: Axura is used for the treatment of patients with moderate to severe Alzheimer's disease.
Croatian: Axura se koristi za liječenje bolesnika s umjerenom do teškom Alzheimerovom bolešću.
English: The solution also contains potassium sorbate and sorbitol (E 420).
Croatian: Otopina također sadrži kalijev sorbat i sorbitol (E 420).
English: The other ingredients are: potassium sorbate, sorbitol (E 420) and purified water.
Croatian: Drugi sastojci su: kalijev sorbat, sorbitol E 420 i pročišćena voda.
English: How to take Axura
Croatian: Kako uzimati Axuru
English: Film-coated tablet.
Croatian: Filmom obložene tablete.
English: Each pack of 28 film-coated tablets for a 4 week treatment schedule contains: 7 x Axura 5 mg
Croatian: Svako pakiranje s 28 filmom obloženih tableta za plan liječenja za 4 tjedna sadrži: 7 x Axura 5 mg
English: The recommended dose of Axura for adults and older people is four pump actuations, equivalent to 20 mg once a day.
Croatian: Preporučena doza Axure za odrasle i starije osobe je četiri potiska pumpice, što odgovara 20 mg jednom dnevno.
English: In these situations the treatment should be carefully supervised, and the clinical benefit of Axura reassessed by your doctor on a regular basis.
Croatian: U tim slučajevima liječenje mora biti pažljivo nadzirano, a Vaš liječnik treba redovito ponovno procjenjivati kliničku korist od uzimanja Axure.
English: The dosing pump must only be used with the Axura solution in the bottle provided, not for other substances or containers.
Croatian: Pumpica za doziranje smije se koristiti samo za Axura otopinu u predviđenoj boci, a ne za druge tvari ili spremnike.
English: Axura belongs to a group of medicines called NMDAreceptor antagonists.
Croatian: Axura spada u skupinu lijekova poznatih kao antagonisti NMDA receptora.
English: - if you are allergic (hypersensitive) to memantine hydrochloride or any of the other ingredients of Axura tablets (listed in section 6).
Croatian: - ako ste alergični (preosjetljivi) na memantinklorid ili neki drugi sastojak Axura tableta (naveden u dijelu 6).
English: The recommended dose of Axura for adults and older people is 20 mg once a day.
Croatian: Preporučena doza Axure za odrasle i starije osobe je 20 mg jednom dnevno.
English: The following Adverse Reactions listed in the Table below have been accumulated in clinical studies with Axura and since its introduction in the market.
Croatian: U sljedećoj tablici prikazane su nuspojave prikupljene tijekom kliničkih ispitivanja s Axurom i nakon stavljanja lijeka u promet.
English: In postmarketing experience these events have been reported in patients treated with Axura.
Croatian: Ovi su događaji prijavljeni u postmarketinškom razdoblju kod bolesnika liječenih Axurom.
English: Axura oral solution is presented as a clear, colourless to light yellowish solution.
Croatian: Axura oralna otopina je bistra, bezbojna do svijetlo žućkasta otopina.
English: Women taking Axura should not breast-feed.
Croatian: Žene koje uzimaju Axuru ne smiju dojiti.
English: EU/1/02/218/016 28 film-coated tablets EU/1/02/218/023 28 film-coated tablets
Croatian: EU/1/02/218/016 28 filmom obloženih tableta EU/1/02/218/023 28 filmom obloženih tableta
English: Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets EU/1/02/218/016
Croatian: Axura 5 mg+10 mg+15 mg+20 mg filmom obložene tablete EU/1/02/218/016
English: For removing the screw cap from the bottle the cap must be turned anticlockwise and unscrewed completely (fig. 1).
Croatian: Za uklanjanje zatvarača s navojem s boce, zatvarač se mora okrenuti u smjeru suprotnom od kazaljke na satu i potpuno odvrnuti (sl. 1).
English: Axura 10 mg film-coated tablets EU/1/02/218/001
Croatian: Axura 10 mg filmom obložene tablete EU/1/02/218/001
English: Axura 20 mg film-coated tablets EU/1/02/218/017
Croatian: Axura 20 mg filmom obložene tablete EU/1/02/218/017
English: Week 2 (day 8-14): The patient should take 1 ml solution (10 mg) equivalent to two pump actuations per day for 7 days.
Croatian: 2. tjedan (8.-14. dan): Bolesnik treba uzimati 1 ml otopine (10 mg) što odgovara dva potiska pumpice dnevno, tijekom 7 dana.
English: Axura contains the active substance memantine hydrochloride.
Croatian: Axura sadrži djelatnu tvar memantinklorid.
English: Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMA) http://www.ema.europa.eu.
Croatian: Detaljnije informacije o ovom lijeku dostupne su na web stranici Europske agencije za lijekove (EMA) http://www.ema.europa.eu.
English: Axura 5 mg, 10 mg, 15 mg, 20 mg tablets
Croatian: Axura 5 mg, 10 mg, 15 mg, 20 mg tablete
English: Axura 20 mg tablets
Croatian: Axura 20 mg tablete
English: Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets The 5 mg film-coated tablets are white to off-white, oval-oblong film-coated tablets with imprint ‘5' on one side and imprint ‘MEM' on the other side.
Croatian: Axura 5 mg+10 mg+15 mg+20 mg filmom obložene tablete Filmom obložene tablete od 5 mg su bijele do gotovo bijele, ovalno duguljaste filmom obložene tablete s utisnutom oznakom ‘5' na jednoj strani i ‘MEM' na drugoj strani.
English: Potassium sorbate Sorbitol E 420
Croatian: 6.1 Popis pomoćnih tvari kalijev sorbat sorbitol E 420
English: Axura 10 mg tablets
Croatian: Axura 10 mg tablete
English: EU/1/02/218/022 840 film-coated tablets (20 packs of 42) EU/1/02/218/029 840 film-coated tablets (20 packs of 42)
Croatian: EU/1/02/218/022 840 filmom obloženih tableta (20 pakiranja po 42) EU/1/02/218/029 840 filmom obloženih tableta (20 pakiranja po 42)
English: Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets Each filmcoated tablet contains 5 mg of memantine hydrochloride equivalent to 4.15 mg memantine.
Croatian: Axura 5 mg+10 mg+15 mg+20 mg filmom obložene tablete Svaka filmom obložena tableta sadrži 5 mg memantinklorida, što odgovara 4,15 mg memantina.